Back to Journals » Drug Design, Development and Therapy » Volume 11

Paeoniflorin attenuates incipient diabetic nephropathy in streptozotocin-induced mice by the suppression of the Toll-like receptor-2 signaling pathway

Authors Shao YX, Xu XX, Wang K, Qi XM, Wu YG

Received 18 August 2017

Accepted for publication 7 October 2017

Published 9 November 2017 Volume 2017:11 Pages 3221—3233

DOI https://doi.org/10.2147/DDDT.S149504

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Junhua Mai

Peer reviewer comments 2

Editor who approved publication: Dr Qiongyu Guo

Yun-xia Shao,1,2 Xing-xin Xu,1 Kun Wang,1 Xiang-ming Qi,1 Yong-gui Wu1

1Department of Nephrology, The First Affiliated Hospital, Anhui Medical University, Hefei, 2Department of Nephrology, The Second People’s Hospital of Wuhu, Wuhu, Anhui, People’s Republic of China

Abstract: Toll-like receptors (TLRs) may be involved in diabetic nephropathy (DN). Paeoniflorin (PF) is an effective Chinese traditional medicine with anti-inflammatory and immunoregulatory effects that may inhibit the TLR2 signaling pathway. In this study, we investigated the effects of PF on the kidneys of mice with streptozotocin-induced type 1 diabetes mellitus using TLR2 knockout mice (TLR2-/-) and wild-type littermates (C57BL/6J-WT). After 12 weeks of intraperitoneal injection of PF at doses of 25, 50, and 100 mg/kg once a day, diabetic mice had significantly reduced albuminuria and attenuated renal histopathology. These changes were associated with substantially alleviated macrophage infiltration and decreased expression of TLR2 signaling pathway biomarkers. These data support a role of TLR2 in promoting inflammation and indicate that the effect of PF is associated with the inhibition of the TLR2 pathway in the kidneys of diabetic mice. PF thus shows therapeutic potential for the prevention and treatment of DN.

Keywords: paeoniflorin, Toll-like receptors 2, TLR2, diabetic nephropathy, DN, inflammation, macrophages
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]